Citadel Advisors’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-40,700
| Closed | -$17K | – | 10376 |
|
|
2018
Q4 | $17K | Buy |
40,700
+12,600
| +45% | +$7.83K | ﹤0.01% | 8813 |
|
|
2018
Q3 | $27K | Sell |
28,100
-13,900
| -33% | -$23.3K | ﹤0.01% | 8958 |
|
|
2018
Q2 | $102K | Buy |
42,000
+26,300
| +168% | +$64.4K | ﹤0.01% | 8231 |
|
|
2018
Q1 | $38K | Buy |
15,700
+4,200
| +37% | +$10.6K | ﹤0.01% | 8001 |
|
|
2017
Q4 | $28K | Sell |
11,500
-2,600
| -18% | -$7.19K | ﹤0.01% | 7780 |
|
|
2017
Q3 | $44K | Sell |
14,100
-5,100
| -27% | -$16.4K | ﹤0.01% | 7212 |
|
|
2017
Q2 | $77K | Buy |
+19,200
| New | +$83.6K | ﹤0.01% | 6994 |
|
|
2016
Q3 | – | Sell |
-3,170
| Closed | -$14K | – | 8193 |
|
|
2016
Q2 | $14K | Buy |
+3,170
| New | +$20.7K | ﹤0.01% | 6702 |
|
|
2016
Q1 | – | Sell |
-820
| Closed | -$24K | – | 8918 |
|
|
2015
Q4 | $24K | Buy |
820
+570
| +228% | +$17.2K | ﹤0.01% | 7819 |
|
|
2015
Q3 | $8K | Sell |
250
-250
| -50% | -$12K | ﹤0.01% | 8552 |
|
|
2015
Q2 | $30K | Sell |
500
-1,070
| -68% | -$75.5K | ﹤0.01% | 7969 |
|
|
2015
Q1 | $168K | Hold |
1,570
| – | – | ﹤0.01% | 6361 |
|
|
2014
Q4 | $147K | Buy |
1,570
+1,450
| +1,208% | +$138K | ﹤0.01% | 6304 |
|
|
2014
Q3 | $9K | Buy |
120
+40
| +50% | +$3.15K | ﹤0.01% | 7793 |
|
|
2014
Q2 | $7K | Buy |
+80
| New | +$4.9K | ﹤0.01% | 7685 |
|
Citadel Advisors's PTX Position: Q1 2019 in Review
Citadel Advisors sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2019, closing a stake of 36,554 shares — an estimated $15K sold.
Citadel Advisors first reported a position in PTX in Q2 2014 and held it in 11 quarters. The position peaked at $1.92M in Q1 2015. 1 fund tracked by Wall St. Rank holds PTX as of Q1 2019.
- Citadel Advisors reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2019 after selling out during the quarter.
- Citadel Advisors sold 36,554 Pernix Therapeutics Holdings, Inc. shares in Q1 2019, an estimated $15K.
- Citadel Advisors first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2014 and held it in 11 quarters.
- Citadel Advisors's Pernix Therapeutics Holdings, Inc. position peaked at $1.92M in Q1 2015.
- 1 fund tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2019.
Based on Citadel Advisors's 13F filing for Q1 2019, filed 15 May 2019.